cas 1449598-86-0|| where to buy 2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Produktname:2-Chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

IUPAC Name:2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM337294-1g	in stock	ȎưȎ
CM337294-10g	in stock	Ǌƞƞŉ
CM337294-100g	in stock	ŢǯŢŉ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1449598-86-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1449598-86-0; Molekulare Formel:C8H4ClFN2O; Schmelzpunkt:-; SMILES-Code:O=C1C=C(Cl)N=C2N1C=C(F)C=C2; Dichte:

: Katalognummer:CM337294; Molekulargewicht:198.58; Siedepunkt:; Mdl-Nr.:MFCD28659052; Lagerung:

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.